Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...
3d
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive ...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback